Chronic coronary artery disease. Atherosclertic heart disease
Conditions
Interventions
Intervention 1: Oral Angipars (1 Cap/BD) for 12 weeks as well as Intravenous Angipars (Infusion of 1 Amp/week) for 12 weeks. Intervention 2: Intravenous Angipars (Infusion of 1 Amp/week) for 12 weeks
Treatment - Drugs
Oral Angipars (1 Cap/BD) for 12 weeks as well as Intravenous Angipars (Infusion of 1 Amp/week) for 12 weeks
Intravenous Angipars (Infusion of 1 Amp/week) for 12 weeks / No Control
Sponsors
Pars Roos Company
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion Criteria: 1- Proven Coronary Artery Disease (CAD) 2- Unsuitable for Coronary Artery Bypass Graft (CABG) or Percutaneous Intervention (PCI) 3- Ejection Fraction (EF) < %40 Exclusion Criteria: 1- Simultaneous valvular disease (moderate or severe) 2- Debilitating or severe co-morbidity (neurological impairment, respiratory or renal or liver diseases or cancers) 3- Enrolment in another Clinical Trail in previous 3 month 4- non-compliance 5- Severe or unstable clinical feathers 6- Overt heart failure
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical and Paraclinical Signs and Symptoms of Cardiac Ischemia. Timepoint: Every week for 12 weeks. Method of measurement: Past Medical History, Physical Examination, Functional Class and Life Style, Biochemical Tests, EKG, Perfusion Scan, Stress Echocardiography and . | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Rezaei
Cardiac Transplantation Research Center (CTRC)
Outcome results
None listed